

**REMARKS**

In an Office Action mailed March 1, 2007, claims 1, 33 and 45 – 47 stand rejected. Claims 2 – 32 and 35 are objected to. Claims 1-33, 35, and 45-47 are currently pending. Claim 25 was amended to correct a typographical error. An Information Disclosure Statement and references are provided.

**35 U.S.C. §112, 2<sup>nd</sup> paragraph**

Claim 33 was rejected under 35 U.S.C. § 112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner stated that the scope of the term "further comprising" is unclear. Claim 33 has been amended for clarification. Support for the amendment may be found the specification at page 8. Applicant respectfully requests withdrawal of the rejection of claim 33 under 35 U.S.C. §112, 2<sup>nd</sup> paragraph.

**35 U.S.C. § 112, 1<sup>st</sup> paragraph**

Claims 1 and 33 were rejected under 35 U.S.C. § 112, first paragraph for failing to provide enablement for "physiological functional derivatives thereof." Claims 1 and 33 have been amended to recite salts and solvates. Support for the amendment to claims 1 and 33 is provided in the specification at pages 14 - 15.

Claims 45 – 47 were rejected under 35 U.S.C. § 112, first paragraph because the specification is not enabling for the prophylaxis of papovavirus or the treatment or prophylaxis of all oncogenic viruses such as adenoviruses and retroviruses. Claims 45 – 47 were amended to recite treatment of papovavirus infections. Support for the amendment to claims 45 – 47 is provided in the specification at pages 22 and 53 – 55.

Applicants respectfully request withdrawal of the rejection of claims 1, 33, and 45 – 47 under 35 U.S.C. § 112, first paragraph.

Claim objections

Applicants submit that the amendment to claim 1 obviates the objection to claims 2 – 32 and 35.

Applicants respectfully submit that the present application is in condition for allowance. An early consideration and Notice of Allowance is earnestly solicited.

Applicants hereby request a 3-month extension of time to extend the response period up to and including September 1, 2007. The Commissioner is hereby authorized to charge such fees and any other fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,



Karen L. Prus  
Attorney for Applicant  
Registration No. 39,337

Date: *August 28, 2007*  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-2192  
Facsimile: 919-483-7988